Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs Low-dose Glucocorticoids in RA
NCT05606107Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Disease Activity Score 28-joint count C-reactive protein at 24 weeks. Status: unknown.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05606107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606107.